CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-02-18 DOI:10.1186/s13550-025-01203-z

Ya Han, Shuo Cao, Jie Liu, Binbin Ding, Shijie Wang, Jihong Pan, Yongpeng Ge, Kai Cheng, Lin Wang, Luna Ge

{"title":"CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response.","authors":"Ya Han, Shuo Cao, Jie Liu, Binbin Ding, Shijie Wang, Jihong Pan, Yongpeng Ge, Kai Cheng, Lin Wang, Luna Ge","doi":"10.1186/s13550-025-01203-z","DOIUrl":null,"url":null,"abstract":"Background: Rheumatoid arthritis (RA) is a common chronic, inflammatory autoimmune disease, and early clinical diagnosis is crucial for its treatment. CXCR4 expression was characterized in arthritic mouse models and joints of RA patients, and [18 F]AIF-NOTA-QHA-04 specificity was assessed in non-malignant cells with elevated CXCR4 expression. This study explored the application of CXCR4-targeted PET probe [18 F]AIF-NOTA-QHA-04 in monitoring disease activity and therapeutic efficacy in RA. To this aim, the metabolic characteristics of [18 F]AIF-NOTA-QHA-04 and correlation of [18 F]AIF-NOTA-QHA-04 uptake with arthritis severity were evaluated by PET imaging in arthritic mice. [18 F]AIF-NOTA-QHA-04 potential in evaluating therapeutic efficacy was further investigated in arthritic mice following methotrexate (MTX) and etanercept (ETC) treatment.Results: CXCR4 expression was significantly increased in the inflamed joints of collagen-induced arthritis (CIA) and collagen-antibody induced arthritic (CAIA) mice, and in synovial tissues of RA patients. [18 F]AIF-NOTA-QHA-04 showed high specificity for CXCR4, with increased probe uptake in arthritic joints that was strongly correlated with arthritis severity scores. PET imaging revealed that increased uptake of [18 F]AIF-NOTA-QHA-04 in arthritic joints paralleled disease activity, with uptake decreasing upon remission. Furthermore, [18 F]AIF-NOTA-QHA-04 PET imaging provided earlier and more sensitive assessments of the efficacy of MTX and ETC compared to traditional methods.Conclusion: The CXCR4-targeted PET probe [18 F]AIF-NOTA-QHA-04 is a promising tool for RA diagnosis and monitoring, with high specificity and sensitivity. The potential of this probe as a biomarker for disease activity and therapeutic response underscores its value in personalized medication strategies for the management of RA.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"10"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01203-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Rheumatoid arthritis (RA) is a common chronic, inflammatory autoimmune disease, and early clinical diagnosis is crucial for its treatment. CXCR4 expression was characterized in arthritic mouse models and joints of RA patients, and [¹⁸ F]AIF-NOTA-QHA-04 specificity was assessed in non-malignant cells with elevated CXCR4 expression. This study explored the application of CXCR4-targeted PET probe [¹⁸ F]AIF-NOTA-QHA-04 in monitoring disease activity and therapeutic efficacy in RA. To this aim, the metabolic characteristics of [¹⁸ F]AIF-NOTA-QHA-04 and correlation of [¹⁸ F]AIF-NOTA-QHA-04 uptake with arthritis severity were evaluated by PET imaging in arthritic mice. [¹⁸ F]AIF-NOTA-QHA-04 potential in evaluating therapeutic efficacy was further investigated in arthritic mice following methotrexate (MTX) and etanercept (ETC) treatment.

Results: CXCR4 expression was significantly increased in the inflamed joints of collagen-induced arthritis (CIA) and collagen-antibody induced arthritic (CAIA) mice, and in synovial tissues of RA patients. [¹⁸ F]AIF-NOTA-QHA-04 showed high specificity for CXCR4, with increased probe uptake in arthritic joints that was strongly correlated with arthritis severity scores. PET imaging revealed that increased uptake of [¹⁸ F]AIF-NOTA-QHA-04 in arthritic joints paralleled disease activity, with uptake decreasing upon remission. Furthermore, [¹⁸ F]AIF-NOTA-QHA-04 PET imaging provided earlier and more sensitive assessments of the efficacy of MTX and ETC compared to traditional methods.

Conclusion: The CXCR4-targeted PET probe [¹⁸ F]AIF-NOTA-QHA-04 is a promising tool for RA diagnosis and monitoring, with high specificity and sensitivity. The potential of this probe as a biomarker for disease activity and therapeutic response underscores its value in personalized medication strategies for the management of RA.

查看原文本刊更多论文

类风湿性关节炎的cxcr4靶向PET成像：一种监测疾病活动性和治疗反应的新方法

背景：类风湿关节炎（RA）是一种常见的慢性炎症性自身免疫性疾病，临床早期诊断对其治疗至关重要。在关节炎小鼠模型和RA患者关节中表征了CXCR4的表达，[18 F]在CXCR4表达升高的非恶性细胞中评估了AIF-NOTA-QHA-04的特异性。本研究探讨了cxcr4靶向PET探针[18 F]AIF-NOTA-QHA-04在RA疾病活动性监测及治疗效果中的应用。为此，我们在关节炎小鼠中通过PET显像评估[18 F]AIF-NOTA-QHA-04的代谢特性以及[18 F]AIF-NOTA-QHA-04摄取与关节炎严重程度的相关性。[18 F]进一步研究了AIF-NOTA-QHA-04在甲氨蝶呤（MTX）和依那西普（ETC）治疗关节炎小鼠中的疗效评价潜力。结果：CXCR4在胶原诱导关节炎（CIA）和胶原抗体诱导关节炎（CAIA）小鼠炎症关节以及RA患者滑膜组织中的表达显著升高。[18 F]AIF-NOTA-QHA-04对CXCR4表现出高特异性，在关节炎关节中探针摄取增加，与关节炎严重程度评分密切相关。PET成像显示，关节炎关节中[18 F]AIF-NOTA-QHA-04的摄取增加与疾病活动平行，随着病情缓解，摄取减少。此外[18 F]，与传统方法相比，AIF-NOTA-QHA-04 PET成像可以更早、更灵敏地评估MTX和ETC的疗效。结论：cxcr4靶向PET探针[18 F]AIF-NOTA-QHA-04具有较高的特异性和敏感性，是一种很有前景的RA诊断和监测工具。该探针作为疾病活动性和治疗反应的生物标志物的潜力强调了其在RA管理的个性化药物策略中的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.